Correction to: Oncogene https://doi.org/10.1038/s41388-019-1059-0, published online 15 October 2019
In this article the wrong figure appeared as Fig. 2b.; the figure should have appeared as shown below.
Previously published Fig. 2b:
Figure 2. Effect of V2R antagonists on growth of RCC cell lines:
New Fig. 2b:
Correct Figure 2B with 6-well plates for Caki-1 and 760 cells treated with OPC31260
The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sinha, S., Dwivedi, N., Tao, S. et al. Correction: Targeting the vasopressin type-2 receptor for renal cell carcinoma therapy. Oncogene 44, 632–633 (2025). https://doi.org/10.1038/s41388-025-03279-2
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41388-025-03279-2
